Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.
Jean Carlos Lipreri da SilvaJuan Luiz Coelho-SilvaKeli LimaHugo Passos VicariMariana LazariniLeticia Veras Costa-LotufoFabiola TrainaJoão Agostinho Machado-NetoPublished in: Cellular oncology (Dordrecht) (2021)
From our data we conclude that EZR expression may serve as a prognostic factor in AML. Our preclinical findings indicate that ezrin inhibitors may be employed as a putative novel class of AML targeting drugs.
Keyphrases
- prognostic factors
- acute myeloid leukemia
- genome wide
- poor prognosis
- allogeneic hematopoietic stem cell transplantation
- electronic health record
- transcription factor
- dna methylation
- cancer therapy
- big data
- binding protein
- cell therapy
- genome wide identification
- single molecule
- bioinformatics analysis
- machine learning
- acute lymphoblastic leukemia
- mesenchymal stem cells
- artificial intelligence
- data analysis
- genome wide analysis